Peptidoglycan biosynthesis machinery (membrane-associated)

The membrane-associated peptidoglycan biosynthesis machinery in Staphylococcus aureus is a multi-enzyme pathway responsible for the assembly and translocation of the bacterial cell wall's primary structural component. This process involves the sequential action of enzymes such as MraY and MurG, which synthesize the lipid-linked precursors Lipid I and Lipid II on the cytoplasmic side of the membrane (PubMed: 25561184). Lipid II is subsequently flipped across the membrane to the periplasmic space, where it serves as the substrate for penicillin-binding proteins (PBPs) that catalyze transglycosylation and transpeptidation reactions (StatPearls: NBK441868). These steps are vital for maintaining the osmotic integrity and shape of the bacterium, making the machinery a high-priority target for antimicrobial agents. Antibiotics targeting this machinery operate through diverse mechanisms, such as the sequestration of Lipid II by glycopeptides like vancomycin or the inhibition of PBP-mediated cross-linking by beta-lactams (NCBI: PMC3161644). In S. aureus, the evolution of resistance mechanisms, most notably the expression of the alternative transpeptidase PBP2a in MRSA strains, significantly complicates treatment by reducing drug binding affinity (Nature: 10.1038/nature14098). Because these biosynthetic processes are absent in eukaryotic cells, they offer a high therapeutic index, though the emergence of multi-drug resistant phenotypes remains a critical concern in clinical settings.

Other names

Lipid II cycleCell wall synthesis pathwayMembrane-associated peptidoglycan synthesisMraY-MurG pathwayPeptidoglycan biosynthesis pathway

Inhibition of Lipid II synthesis, sequestration of cell wall precursors, and inhibition of peptidoglycan cross-linking.